Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
34.95 USD | +2.64% | +5.97% | +62.41% |
May. 15 | Spyre Therapeutics, Inc. Announces Board Changes | CI |
May. 13 | Wells Fargo Adjusts Price Target on Spyre Therapeutics to $40 From $35, Maintains Overweight Rating | MT |
Business Summary
Number of employees: 30
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Human Enzyme Therapeutics
100.0
%
| 2 | 100.0 % | 1 | 100.0 % | -61.96% |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
100.0
%
| 2 | 100.0 % | 1 | 100.0 % | -61.96% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Cameron Turtle
CEO | Chief Executive Officer | 34 | 23-06-21 |
Scott Burrows
DFI | Director of Finance/CFO | 47 | 23-08-31 |
Brian Connolly
CTO | Chief Tech/Sci/R&D Officer | - | Nov. 26 |
Chief Tech/Sci/R&D Officer | 56 | 14-01-31 | |
Mira Huyghe
PRN | Corporate Officer/Principal | - | Nov. 26 |
Deanna Nguyen
PRN | Corporate Officer/Principal | - | Nov. 26 |
Joshua Friedman
PRN | Corporate Officer/Principal | - | Nov. 26 |
General Counsel | 41 | 23-09-04 | |
Paul Fehlner
PRN | Corporate Officer/Principal | 61 | Nov. 26 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Tomas Kiselak
BRD | Director/Board Member | 37 | 23-06-21 |
Jeffrey Albers
BRD | Director/Board Member | 52 | Nov. 26 |
Peter Harwin
BRD | Director/Board Member | 38 | 23-06-21 |
Laurie Stelzer
BRD | Director/Board Member | 56 | Nov. 26 |
Director/Board Member | 34 | 23-06-21 | |
Mark Mckenna
BRD | Director/Board Member | 44 | Jan. 31 |
Cameron Turtle
CEO | Chief Executive Officer | 34 | 23-06-21 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 0 | 271,625 | 0 | 0 | 70.36 % |
Stock B | 1 | 50,782,384 | 35,728,470 ( 70.36 %) | 0 | |
Stock C | 0 | 437,037 | 0 | 0 |
Company contact information
Spyre Therapeutics, Inc.
Building 17 221 Crescent Street
02453, Waltham
+617 651 5940
http://www.aeglea.comSector
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+62.41% | 1.77B | |
+11.91% | 118B | |
+11.60% | 106B | |
-4.68% | 24.28B | |
-0.82% | 21.96B | |
-10.12% | 18.16B | |
-42.12% | 16.37B | |
-17.47% | 15.56B | |
+2.77% | 13.63B | |
+34.58% | 12.27B |
- Stock Market
- Equities
- SYRE Stock
- Company Spyre Therapeutics, Inc.